J. Comp. Path. 2016, Vol. ■, 1–9

Available online at www.sciencedirect.com

ScienceDirect



NEOPLASTIC DISEASE

Immunohistochemical Labelling for Cyclo-oxygenase-2: Does the Positive Control Guarantee Standardized Results?

S. Belluco^{*}, P. Carnier[†], M. Castagnaro[†], K. Chiers[‡], F. Millanta[§], L. Peña^{||}, I. Pires[¶], F. Queiroga[¶], S. Riffard[#], T. Scase^{††} and G. Polton^{‡‡}

* Equipe Recherche UPSP ICE 2011-03-101: Oncology, Vetagro-sup, Campus Vétérinaire, 1 Avenue Bourgelat, Marcy l'etoile, France, [†] Department of Comparative Biomedicine and Food Science, Faculty of Veterinary Medicine, AGRIPOLIS, Viale dell'Università 16, Legnaro, Italy, [‡] Faculty of Veterinary Medicine, University of Ghent, Salisburylaan 133, Merelbeke, Belgium, [§] Department of Animal Pathology, School of Veterinary Medicine, University of Pisa, Viale delle Piagge 2, Pisa, Italy, [∥] Veterinary School, Complutense University Madrid, Madrid, Spain, [¶] University of Trás-os-Montes and Alto Douro, Quinta de Prados, Vila Real, Portugal, [#] Merial, 254 rue Marcel Mérieux, Lyon, France, ^{††} Bridge Pathology Ltd., Courtyard House, 26A Oakfield Road, Bristol and ^{‡‡} North Downs Specialist Referrals, Friesian Building 3&4, The Brewer Street Dairy Business Park, Brewer Street, Bletchingley, Surrey, UK

Summary

Since the identification of cyclo-oxygenase-2 as a potentially important therapeutic target in veterinary oncology, numerous studies on its expression have been conducted. Unfortunately, results have been heterogeneous and conclusions are difficult to draw. We tested the ability of a defined positive control to guarantee reproducibility of results among different laboratories. Valid positive controls were defined by positivity of the renal macula densa without background labelling. Fifteen colorectal tumours and 15 oral squamous cell carcinomas were labelled immunohistochemically by six European laboratories. Slides were evaluated in blinded fashion for percentage of positive cells and labelling intensity by three pathologists, and results were analyzed statistically for reproducibility and inter-reader variability. Macula densa positivity was an insufficiently sensitive control to guarantee reproducible results for percentage of positive cells and labelling intensity. Inter-reader variability was proven statistically, making the case for image analysis or other automated quantitative evaluation techniques.

© 2016 Elsevier Ltd. All rights reserved.

Keywords: cyclo-oxygenase-2; immunohistochemistry; inter-reader variability; reproducibility

Introduction

Cyclo-oxygenase (COX) is an enzyme that takes part in the conversion of arachidonic acid to proinflammatory prostaglandins (Dore, 2011). The COX enzyme system comprises three isoforms: COX-1, which is constitutively expressed in most tissues and participates in several normal physiological activities; COX-2, which is normally absent (except in a small number of tissues such as placenta, brain and kidney); and COX-3, apparently expressed in brain and spinal cord and whose existence and functions remain to be elucidated (Dore, 2011). Specific mechanisms whereby COX-2 contributes to tumour development and progression are inhibition of cellular apoptosis and stimulation of cell proliferation, cell survival, tumour invasion and angiogenesis (Sobolewski *et al.*, 2010; Dore, 2011). In human medicine, its prognostic significance is well established for several tumours, where higher levels

 $Correspondence \ to: \ S. \ Belluco \ (e-mail: \ sara.belluco @vetagro-sup.fr).$

0021-9975/\$ - see front matter http://dx.doi.org/10.1016/j.jcpa.2016.01.003 © 2016 Elsevier Ltd. All rights reserved.

Please cite this article in press as: Belluco S, et al., Immunohistochemical Labelling for Cyclo-oxygenase-2: Does the Positive Control Guarantee Standardized Results?, Journal of Comparative Pathology (2016), http://dx.doi.org/10.1016/j.jcpa.2016.01.003

S. Belluco et al.

of COX-2 expression correlate with a shorter survival time and the long-term use of non-steroidal antiinflammatory drugs has been shown to reduce the incidence of tumour development (Sobolewski et al., 2010; Dore, 2011). In dogs, COX-2 expression has been reported in several tumours, including intestinal adenocarcinomas (McEntee et al., 2002; Knottenbelt et al., 2006), oral squamous cell carcinomas (Pestili de Almeida et al., 2001; Mohammed et al., 2004; Pires et al., 2010), bladder tumours (Knottenbelt et al., 2006; Sledge et al., 2015), haemangiosarcomas (Heller et al., 2005a), histiocytic tumours (Heller et al., 2005a), mammary tumours (Dore et al., 2003; Millanta et al., 2006, 2014; Dias Pereira et al., 2009; Lavalle et al., 2009; Queiroga et al., 2010; Clemente et al., 2013), mast cell tumours (Heller et al., 2005a; Prada et al., 2012), ovarian carcinomas (Borzacchiello et al., 2007), nasal carcinomas (Impellizeri and Esplin, 2008; Belshaw et al., 2011) and renal carcinomas (Khan et al., 2001). Unfortunately, the immunohistochemical findings with regard to COX-2 expression vary significantly, even for a single tumour type, posing a problem of interpretation for clinicians and researchers.

Taking mammary tumours as an example, depending on the study, the percentage of immunohistochemically-positive samples ranged from 0% to 100% in normal tissue, from 20% to 100% in adenomas and from 56% to 100% in adenocarcinomas (Dore *et al.*, 2003; Heller *et al.*, 2005b; Millanta *et al.*, 2006, 2014; Queiroga *et al.*, 2007; Dias Pereira *et al.*, 2009; Lavalle *et al.*, 2009).

In an attempt to understand this discrepancy between results for different COX-2 expression studies performed with canine tumour specimens, we examined the reproducibility (no inter-laboratory variability) of COX-2 immunohistochemistry (IHC), using a defined positive control as the only parameter to guarantee inter-laboratory standardization and analyzing inter-observer variability of the obtained labelling.

Materials and Methods

Since COX-2 is expressed in the renal macula densa of man and several animals, fetal or neonatal kidneys are considered an appropriate positive control for the immunohistochemical study of expression of this antigen (Radi, 2009; Smith *et al.*, 2012). In the present study, the positive control consisted of sections of the kidney of a 1-day-old puppy. The organ was collected during a necropsy examination, which was performed <12 h after death. The specimen was fixed in 10% neutral buffered formalin for approximately 48 h prior to routine processing and embedding in paraffin wax. Six independent European veterinary pathology laboratories received sets of almost identical slides containing serial sections (4 μ m) from archived paraffin wax-embedded samples. Each slide set included one section each of 15 colorectal adenocarcinomas and of 15 oral squamous cell carcinomas, two sections from the positive control and one slide containing sections of normal organs as negative controls (small and large intestine and pancreas). The protocols applied by each laboratory are provided in Table 1. To further reduce potential variation, the same antibody was used throughout the study (anti COX-2, clone 33, Transduction Laboratories, Lexington, Kentucky, USA).

The positive reaction in the positive control was defined as intense labelling of the macula densa, without any background labelling. Each tumour section was analyzed for the proportion of positively labelled cells and the labelling intensity. The former was scored as: 0%, 1%, 2-9%, 10-30%, 31-60% or 61-100% of labelled cells within the tumour. Intensity was recorded as: -, no labelling; +, weak labelling; ++, moderate labelling; or +++, strong labelling (Queiroga et al., 2007). The reproducibility of the technique and the inter-observer variability were tested by comparing the results obtained by three pathologists (MC, SB and TS), who each read all slides in the six slide sets produced and labelled at each of the six participating laboratories. These slides were encoded and mixed randomly so that the pathologists were blinded to the origin of each slide. To reproduce general research conditions, the three pathologists agreed in advance on the scoring system, but they had not been trained for consensual evaluation of the slides. During the study, they met three times and spent 1 h on each occasion using a multiheaded microscope to agree on the scoring system.

In order to test inter-laboratory variability, simple Kappa and weighted Kappa statistics were calculated. The simple Kappa statistic was accompanied by the corresponding Kappa exact test and weighted Kappa with confidence intervals, in order to assess the agreement of both scores. In order to test interobserver variability, Cochran-Mantel-Haenszel (CMH) statistics were calculated associated with CMH tests, which assess the general association between laboratories and response adjusted for samples. The statistical analyses, conducted using SAS 9.2 software (SAS, Cary, North Carolina, USA), were carried out for the percentage of positively labelled cells and the intensity of the labelling on identical sets of slides. Statistical significance was based on two-tailed tests of the null hypothesis resulting in a P value of 0.05 or less. A quantification of interreader variability was studied on two identical sets

Please cite this article in press as: Belluco S, et al., Immunohistochemical Labelling for Cyclo-oxygenase-2: Does the Positive Control Guarantee Standardized Results?, Journal of Comparative Pathology (2016), http://dx.doi.org/10.1016/j.jcpa.2016.01.003

Download English Version:

https://daneshyari.com/en/article/8500653

Download Persian Version:

https://daneshyari.com/article/8500653

Daneshyari.com